Big Pharma Price To Sales Ratio Over Time

PRM Stock  CAD 13.30  0.18  1.37%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Big Pharma Performance and Big Pharma Correlation.
  
As of the 1st of December 2024, Price To Sales Ratio is likely to grow to 56.35.
Please note, there is a significant difference between Big Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Big Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Big Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:

Cross Equities Price To Sales Ratio Analysis

Compare Big Pharma Split and related stocks such as NovaGold Resources, HPQ Silicon Resources, and Eastwood Bio Medical Price To Sales Ratio Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
201020112012201320142015201620172018201920202021202220232024
NG376KKKKKKKKKKKK6.3 K6.6 K
HPQ3.8 K331331331331331331331331331331331331380361
EBM56.535156.535156.535181.639548.650912811956867.10214510686.6703183165116
IZ47.905924.380424.380424.380424.380424.380424.380424.38046.11332.598212.98557.43156.10413.12752.97

Big Pharma Split and related stocks such as NovaGold Resources, HPQ Silicon Resources, and Eastwood Bio Medical Price To Sales Ratio description

Price to Sales Ratio is figured by comparing Big Pharma Split stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Big Pharma sales, a figure that is much harder to manipulate than other Big Pharma Split multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

My Equities

My Current Equities and Potential Positions

Big Pharma Split
PRM
Specialization
Financial Services, Financial Services
Business Address610 Chartwell Road,
ExchangeToronto Exchange
CAD 13.3

Other Information on Investing in Big Stock

Big Pharma financial ratios help investors to determine whether Big Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Big with respect to the benefits of owning Big Pharma security.